[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版).中华肝脏病杂志,2013,21:177-183.
[2] Farnik H,Bojunga J,Berger A,et al.Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients.Hepatology,2013,58:1270-1276.
[3] 黄湛镰,高志良. 肝衰竭的三重打击及治疗策略. 内科急危重症杂志, 2014,20:154-156.
[4] 叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.中华肝脏病杂志,2009,17:638-640.
[5] 朱洪芳,吴广利,马锋振,等.核苷类似物治疗乙型肝炎病毒相关性肝衰竭的临床观察. 肝脏, 2014, 19:195-197.
[6] 鱼康康,李宁,施光峰. 在争议中迈步向前:慢加急性肝衰竭研究进展. 肝脏, 2014, 19:208-210.
[7] 吴广利,侯敏,王伟,等.38例急性、亚急性肝衰竭患者临床分析.肝脏,2008,13:270-271.
[8] Teo EK,Ostapowicz G,Hussain M,et al. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology,2001,33:972-976.
[9] Ostapowicz G, Fontana RJ, Schidt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med,2002,137:947-954.
[10] 曹欣,陈铿,关玉娟,等. HBV相关慢加急性肝衰竭患者HBsAg水平及病毒载量与近期预后研究. 肝脏,2014,19:819-822.
[11] Sonneveld MJ,Rijckborst V,Boucher CA,et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology,2010,52:1251-1257.
[12] Nguyen T,Thompson AJ,Bowden S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:a perspective on Asia.J Hepatol,2010,52:508-513.
[13] Jaroszewicz J,Calle Serrano B,Wursthorn K,et al.Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus(HBV)-infection:a European perspective.J Hepatol,2010,52:514-522.
[14] Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis HBeAg-positive chronic hepatitis B patients. J Manag Care Pharm,2008,14:21-33.
[15] 张冬琴,张海月,吴吉圆,等. 恩替卡韦与拉米夫定治疗HBV相关性肝衰竭患者疗效Meta分析. 实用肝脏病杂志, 2014,17:606-610. |
